Sysmex Corporation (SSMXY)

OTCMKTS · Delayed Price · Currency is USD
12.57
-0.25 (-1.95%)
Aug 29, 2025, 3:50 PM EDT
-1.95%
Market Cap7.93B
Revenue (ttm)3.48B
Net Income (ttm)327.09M
Shares Outn/a
EPS (ttm)0.52
PE Ratio24.24
Forward PEn/a
Dividend0.24 (1.93%)
Ex-Dividend DateSep 29, 2025
Volume6,035
Average Volume112,128
Open12.60
Previous Close12.82
Day's Range12.55 - 12.60
52-Week Range12.50 - 22.00
Beta0.82
RSI23.43
Earnings DateAug 6, 2025

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co... [Read more]

Sector Healthcare
Founded 1968
Employees 10,533
Stock Exchange OTCMKTS
Ticker Symbol SSMXY
Full Company Profile

Financial Performance

In 2024, Sysmex's revenue was 508.64 billion, an increase of 10.21% compared to the previous year's 461.51 billion. Earnings were 53.67 billion, an increase of 8.12%.

Financial numbers in JPY Financial Statements

News

Sysmex reports FQ1 results

Sysmex (SSMXY) reports FQ1 results: Net sales down 5.6%, operating profit drops 36.5%, and attributable profit declines 58.7%.

25 days ago - Seeking Alpha

Sysmex GAAP EPS of ¥41.70, revenue of ¥242.48B

Sysmex (SSMXY) reports a strong 1H performance with GAAP EPS of ¥41.70 and revenue of ¥242.48B, an impressive 14.0% increase year-over-year.

10 months ago - Seeking Alpha